NLNK NewLink Genetics Corporation

+0.02  (+1%)
Previous Close 1.57
Open 1.57
Price To Book 0.52
Market Cap 59269002
Shares 37,276,102
Volume 265,258
Short Ratio
Av. Daily Volume 587,441

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 data presented at ASCO June 4, 2017. Abstract 105.
GDC-0919 and atezolizumab
Solid tumors
Phase 2 poster presentation at ASCO June 5, 2017.
Indoximod + Sipuleucel-T
Metastatic castration resistant prostate cancer (mCRPC)
Phase randomization portion will not be initiated - noted April 15, 2018.
Indoximod in combination with KEYTRUDA or Opdivo - Indigo301
Melanoma - cancer
Phase 2 data presented at ASCO 2018. Primary endpoint not met.
Indoximod + gemcitabine and nab-paclitaxel
Pancreatic cancer
Phase 3 failed to meet primary endpoint - May 2016
HyperAcute Pancreas - IMPRESS
Surgically resected pancreatic cancer
Phase 3 failed to show improvement in survival.
HyperAcute Pancreas - PILLAR
Pancreatic cancer
Phase 2 trial did not meet endpoints - noted June 2, 2017.
Indoximod + taxane
Cancer - breast
Phase 1b data to be presented at ASH December 2018.
Indoximod plus standard-of-care chemotherapy
Acute myeloid leukemia (AML)
Phase 1 updated data due 2019.
Indoximod in combination with chemotherapy and radiation
Diffuse intrinsic pontine glioma (DIPG)
Phase 1 updated data due 2019.
Solid tumors
Rolling BLA filing has commenced - noted November 13, 2018.
Phase 2 data presented at AACR April 2, 2019. ORR 27%.
NLG207 (CRLX101) and paclitaxel
Platinum-resistant ovarian cancer

Latest News

  1. NewLink Genetics Presents Encouraging Phase 2 Results for NLG207 in Ovarian Cancer at AACR 2019
  2. The Zacks Analyst Blog Highlights: ANI, Kamada, Genomic Health and NewLink
  3. 4 Small Biotech Stocks Likely to Witness More Upside in 2019
  4. Edited Transcript of NLNK earnings conference call or presentation 27-Feb-19 9:30pm GMT
  5. Do Institutions Own Shares In NewLink Genetics Corporation (NASDAQ:NLNK)?
  6. NewLink Genetics Announces Clinical Trial Abstract Presentation at AACR Annual Meeting
  7. NewLink Genetics Reports Fourth Quarter, Year-End 2018 Financial Results and Provides Update for Clinical Programs
  8. NewLink Genetics to Host Its Fourth Quarter and Full Year 2018 Financial Results Conference Call on February 27, 2019
  9. Factors of Influence in 2019, Key Indicators and Opportunity within Marathon Oil, Accuray, United Natural Foods, Systemax, Amgen, and NewLink Genetics — New Research Emphasizes Economic Growth
  10. NewLink Genetics to Participate in the Immuno-Oncology 360° Conference
  11. Before You Buy NewLink Genetics Corporation (NASDAQ:NLNK), Consider Its Volatility
  12. NewLink Genetics Presents Encouraging Updated Phase 1 Data with Indoximod Plus Chemotherapy in Frontline AML in an Oral Session at 2018 ASH Annual Meeting
  13. Does NewLink Genetics Corporation’s (NASDAQ:NLNK) CEO Salary Compare Well With Others?
  14. Edited Transcript of NLNK earnings conference call or presentation 1-Nov-18 8:30pm GMT
  15. NewLink Genetics Announces Merck Has Begun Rolling Submission of Licensure Application for Ebola vaccine V920 (rVSV∆G-ZEBOV-GP) to U.S. Food and Drug Administration
  16. NewLink Genetics Presents Phase 1 Data Supporting Significantly Higher Exposure with Indoximod Prodrug, NLG802, and Biomarker Data from Two Phase 2 Trials Illustrating Indoximod’s Impact on the Tumor Microenvironment at SITC 2018
  17. NewLink Genetics Announces Publication of Abstracts for Presentation at the Society for Immunotherapy for Cancer (SITC) Conference
  18. Analysis: Positioning to Benefit within Mercury, Lincoln Electric, Sprint, Fred's, NewLink Genetics, and El Paso Electric — Research Highlights Growth, Revenue, and Consolidated Results
  19. Is the Options Market Predicting a Spike in NewLink Genetics (NLNK) Stock? (revised)
  20. CORRECTED: NewLink Genetics Reports Third Quarter 2018 Financial Results and Announces Abstracts to Be Presented at Upcoming Medical Meetings